Tetra Bio Pharma Inc V.TBP

Primary Symbol: TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc

<< Previous

Bullboard Posts

Next >>

Post by indaknownewfieon Feb 02, 2020 1:43pm

678 Views

Post# 30631099

Why Wendy Hulton's release make sense

https://www.biospace.com/article/releases/tetra-bio-pharma-provides-management-update-on-commercializing-its-inhalation-drug-caumz-/

TBP has the clinical studies that GW just had removed. That is HUGELY significant. That means TBP can include neuropathic and cancer pain on its product monograph. Opening up the entire pain market for TBP dominance

<< Previous

Bullboard Posts

Next >>

Regulatory clarity for market evolution: Canada’s position in global crypto industry